# SYRE catalysts: Spyre Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/syre/catalysts

> Spyre Therapeutics, Inc. (SYRE) has 9 upcoming catalysts. The next is the SPY772 trial start, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for SYRE?

Spyre Therapeutics, Inc. (SYRE) has 9 upcoming catalysts. The next is the SPY772 trial start, 2027. Press release filed with the SEC (EX-99): "its current and future clinical development activities, including the Company's plans for and timing of cohort initiation and data readouts for the ongoing SKYLINE Phase 2 platform trial and SKYLIGHT Phase 2 trial, the advancement of a potential best-in-class anti-TL1A monotherapy agent into pivotal studies for HS in 2027, and the potential of using SPY772 in future advanced clinical development" [Calendar and source filings](https://sec-api.dev/companies/syre/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001636282-26-000132, https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/spyre-20260930xexx991pd.htm (retrieved 2026-11-12). Last confirmed 2026-11-03. Cite: https://sec-api.dev/companies/syre/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Spyre Therapeutics, Inc. |
| Ticker | SYRE (Nasdaq) |
| SEC CIK | 1636282 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/syre |

## Cash runway

Cash $1.07B as of 2026-09-30; quarterly burn $77.5M; about 41.5 months of runway at that rate (XBRL company facts, accession 0001636282-26-000131).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [SPY001 trial start](https://sec-api.dev/pdufa/spy001) | SYRE |  | completed | "We initiated a Phase 1 clinical trial in healthy volunteers of SPY001 and announced the dosing of our first participant in June 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000049/syre-20250331.htm)) |
| Q1 2025 | [SPY003 trial start](https://sec-api.dev/pdufa/spy003) | SYRE |  | scheduled | "We anticipate initiating a Phase 1 clinical trial in healthy volunteers of SPY003 in the first quarter of 2025, subject to regulatory feedback and approval." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000020/syre-20241231.htm)) |
| January 13, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "The Company expects to report its final and complete fourth quarter and full-year 2024 financial results in late February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/d696348dex991.htm)) |
| February 27, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000022/spyre-20241231xexx991.htm)) |
| Q2 2025 | [SPY002 interim data readout](https://sec-api.dev/pdufa/spy002) | SYRE |  | scheduled | "•In December 2024, the Company announced initiation of first-in-human ("FIH") trials of both SPY002 candidates, with healthy volunteer interim data expected in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm)) |
| mid-2025 | [Entyvio® (vedolizumab) trial start](https://sec-api.dev/pdufa/vedolizumab) | SYRE |  | scheduled | "Based on initial Phase 1 clinical data, the company plans to initiate a Phase 2 platform trial in ulcerative colitis in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/exhibit991-8xkdatarelease.htm)) |
| mid-2025 | [SPY001 trial start](https://sec-api.dev/pdufa/spy001) | SYRE |  | scheduled | "Based on these data, and subject to regulatory feedback, the Company plans to initiate a Phase 2 platform trial in mid-2025 that is expected to ultimately include SPY001, SPY002 (TL1A), SPY003 (IL-23) and combinations thereof." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1636282/000162828024046860/syre-20241112.htm)) |
| Q2 2025 | [Spyre Therapeutics, Inc. interim data readout](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | scheduled | "Phase 1 interim data for both molecules on track for 2Q2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000119312525005015/d696348dex991.htm)) |
| mid-2025 | [SPY001 interim data readout](https://sec-api.dev/pdufa/spy001) | SYRE |  | scheduled | "•Based on these interim results, Spyre plans to advance SPY001 to a Phase 2 clinical trial in UC patients in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm)) |
| mid-2025 | [SPY002 trial start](https://sec-api.dev/pdufa/spy002) | SYRE |  | scheduled | "We also plan to initiate a Phase 2 platform trial of our product candidates in IBD beginning with monotherapies in mid-2025 and subsequent planned addition of combination arms as well as a Phase 2 clinical trial of SPY002 in RA in mid-2025, each subject to regulatory feedback and approval." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000049/syre-20250331.htm)) |
| May 8, 2025 | [SPY003 trial start](https://sec-api.dev/pdufa/spy003) | SYRE |  | completed | "Announced first participant dosed in Phase 1 trial of SPY003, with interim PK and safety data readout on track for the second half of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm)) |
| May 8, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm)) |
| Q3 2025 | [SPY002 interim data readout](https://sec-api.dev/pdufa/spy002) | SYRE |  | scheduled | "•Based on these interim results, SPY002 is expected to advance to the SKYLINE-UC Phase 2 platform trial in the third quarter of 2025, and SPY072 is expected to advance to the SKYWAY-RD Phase 2 basket trial, which is expected to initiate in the third quarter as well." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/spyre-20250630xexx991.htm)) |
| Q3 2025 | [SPY072 trial start](https://sec-api.dev/pdufa/spy072) | SYRE | moderately to severely active RA, PsA, or axSpA | scheduled | "SKYWAY-RD Phase 2 Basket Trial in Rheumatic Diseases (RA, PsA, axSpA) - the Company expects to initiate a Phase 2 randomized and placebo-controlled basket trial of SPY072 in patients with moderately to severely active RA, PsA, or axSpA in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/spyre-20250630xexx991.htm)) |
| 2H 2025 | [SPY003 topline data readout](https://sec-api.dev/pdufa/spy003) | SYRE |  | scheduled | "Announced first participant dosed in Phase 1 trial of SPY003, with interim PK and safety data readout on track for the second half of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm)) |
| August 5, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/spyre-20250630xexx991.htm)) |
| Sep 2025 | [SPY072 trial start](https://sec-api.dev/pdufa/spy072) | SYRE | moderately to severely active RA, PsA, or axSpA | completed | "SKYWAY Phase 2 Basket Trial in Rheumatic Diseases - in September 2025, the Company initiated a Phase 2 randomized and placebo-controlled basket trial of SPY072 in patients with moderately to severely active RA, PsA, or axSpA." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/spyre-20260930xexx991pd.htm)) |
| Q4 2025 | [SPY003 interim data readout](https://sec-api.dev/pdufa/spy003) | SYRE |  | scheduled | "•In March 2025, the Company initiated a first-in-human ("FIH") trial of SPY003, with healthy volunteer interim data expected in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/spyre-20250630xexx991.htm)) |
| November 4, 2025 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000104/spyre-20250930xexx991.htm)) |
| 2026 | [SPY003 trial start](https://sec-api.dev/pdufa/spy003) | SYRE |  | scheduled | "its nonclinical and future clinical development activities, including the timing of data readouts for the ongoing SKYWAY-RD Phase 2 basket trial, plans for and timing of monotherapy/combination arm enrollment, cohort initiation and data readouts for the ongoing SKYLINE-UC Phase 2 platform trial and further clinical evaluation of therapeutic combinations, enrollment of clinical trials, number of data readouts expected to be delivered in 2026 and 2027 and the advancement of SPY003 to the SKYLINE-UC Phase 2 platform trial, and related regulatory feedback" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000104/spyre-20250930xexx991.htm)) |
| 2026 | [Spyre Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | scheduled | "•In January 2025, the Company announced its intent to study one of its anti-TL1A antibodies in RA, with Phase 2 trial initiation expected in mid-2025 and topline results in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628225000050/spyre-20250331xexx991.htm)) |
| February 19, 2026 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000022/spyre-20251231xexx991.htm)) |
| April 13, 2026 | [SPY001 topline data readout](https://sec-api.dev/pdufa/spy001) | SYRE | moderate-to-severely active UC | completed, positive | "On April 13, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1636282/000162828026024831/syre-20260413.htm)) |
| May 5, 2026 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/spyre-20260331xexx991.htm)) |
| June 15, 2026 | [SPY002 topline data readout](https://sec-api.dev/pdufa/spy002) | SYRE |  | completed, positive | "On June 15, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 for the treatment of moderately-to-severely active UC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/syre-20260615.htm)) |
| August 4, 2026 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/spyre-20260630xexx991.htm)) |
| Sep 2026 | [SPY001 topline data readout](https://sec-api.dev/pdufa/spy001) | SYRE |  | scheduled | "Enrollment for Part A has completed, with SPY001 and SPY002 Part A topline induction data announced in Q2 2026, and topline data expected for SPY003 in September 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/spyre-20260630xexx991.htm)) |
| Sep 2026 | [SPY072 topline data readout](https://sec-api.dev/pdufa/spy072) | SYRE |  | scheduled | "Topline proof-of-concept data are expected in September 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000098/spyre-20260630xexx991.htm)) |
| Sep 2026 | [SPY072 trial start](https://sec-api.dev/pdufa/spy072) | SYRE | moderately to severely active HS | completed | "SKYLIGHT Phase 2 Trial in HS - in September 2026, the Company initiated its SKYLIGHT Phase 2 trial of SPY072 in subjects with moderately to severely active HS who are initiating bimekizumab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/spyre-20260930xexx991pd.htm)) |
| September 8, 2026 | [SPY003 topline data readout](https://sec-api.dev/pdufa/spy003) | SYRE |  | completed, positive | "On September 8, 2026, the Company announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY003, an anti-IL-23 being investigated for the treatment of moderately-to-severely active UC." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/syre-20260908.htm)) |
| Q4 2026 | [SPY072 topline data readout](https://sec-api.dev/pdufa/spy072) | SYRE |  | scheduled | "Topline data for SPY072 in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) on track for Q4 2026 and for SPY072 in combination with IL17-A/F in hidradenitis suppurativa (HS) in late 2027 or early 2028" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000105/spyre-20260825xexx991.htm)) |
| Oct 2026 to Jan 2027 | [SPY002-072 topline data readout](https://sec-api.dev/pdufa/spy002-072) | SYRE | Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis | scheduled | "NCT07148414 (A Study of SPY072 in Rheumatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07148414)) |
| October 2026 | [SPY002-072 primary completion](https://sec-api.dev/pdufa/spy002-072) | SYRE | Rheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis | delayed | "NCT07148414 (A Study of SPY072 in Rheumatic Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-31 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07148414)) |
| November 3, 2026 | [Spyre Therapeutics, Inc. earnings report](https://sec-api.dev/companies/syre/catalysts) | SYRE |  | completed | "Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/spyre-20260930xexx991pd.htm)) |
| 2027 | [SPY772 trial start](https://sec-api.dev/pdufa/spy772) | SYRE |  | scheduled | "its current and future clinical development activities, including the Company's plans for and timing of cohort initiation and data readouts for the ongoing SKYLINE Phase 2 platform trial and SKYLIGHT Phase 2 trial, the advancement of a potential best-in-class anti-TL1A monotherapy agent into pivotal studies for HS in 2027, and the potential of using SPY772 in future advanced clinical development" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/spyre-20260930xexx991pd.htm)) |
| 2027 | [SPY002 topline data readout](https://sec-api.dev/pdufa/spy002) | SYRE |  | scheduled | "SKYLINE Part A has demonstrated potential best-in-class results for SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23); SKYLINE Part B evaluating pairwise combinations of these components is enrolling with topline induction data expected in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000113/spyre-spyre003releasexexx9.htm)) |
| June 2027 | [SPY001 primary completion](https://sec-api.dev/pdufa/spy001) | SYRE | Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis | scheduled | "NCT07012395 (A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07012395)) |
| Jun to Sep 2027 | [SPY001 topline data readout](https://sec-api.dev/pdufa/spy001) | SYRE | Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis | scheduled | "NCT07012395 (A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07012395)) |
| Q3 2027 | [SPY003 topline data readout](https://sec-api.dev/pdufa/spy003) | SYRE |  | scheduled | "SKYLINE Part B is enrolling ahead of schedule, enabling the Company to increase enrollment and provide topline induction results for three potential best-in-indication combinations, which are expected in Q3 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636282/000163628226000132/spyre-20260930xexx991pd.htm)) |
| October 2027 | [SPY072 primary completion](https://sec-api.dev/pdufa/spy072) | SYRE | Hidradenitis Suppurativa (HS) | scheduled | "NCT07766005 (A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07766005)) |
| Oct 2027 to Jan 2028 | [SPY072 topline data readout](https://sec-api.dev/pdufa/spy072) | SYRE | Hidradenitis Suppurativa (HS) | scheduled | "NCT07766005 (A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07766005)) |
| Mar to Jun 2029 | [SPY001 topline data readout](https://sec-api.dev/pdufa/spy001) | SYRE | Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis | scheduled | "NCT07652294 (Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07652294)) |
| March 2029 | [SPY001 primary completion](https://sec-api.dev/pdufa/spy001) | SYRE | Ulcerative Colitis; Inflammatory Bowel Diseases; Colitis | scheduled | "NCT07652294 (Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-03-02 (ESTIMATED); Lead Sponsor Spyre Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07652294)) |

## Drugs

- [SPY001](https://sec-api.dev/pdufa/spy001): moderate-to-severely active uc, Ulcerative Colitis
- [SPY002](https://sec-api.dev/pdufa/spy002): moderately-to-severely active uc
- [SPY002-072](https://sec-api.dev/pdufa/spy002-072): Rheumatoid Arthritis
- [SPY003](https://sec-api.dev/pdufa/spy003): moderately-to-severely active uc
- [SPY072](https://sec-api.dev/pdufa/spy072): moderately to severely active ra, psa, or axspa, moderately to severely active rheumatic arthritis, moderately to severely active hs, Hidradenitis Suppurativa (HS)
- [SPY772](https://sec-api.dev/pdufa/spy772): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/syre/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SYRE catalysts: Spyre Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/syre/catalysts

```bibtex
@misc{secapidev_companies_syre_catalysts_20261116,
  title        = {SYRE catalysts: Spyre Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/syre/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_syre_catalysts_20261116","title":"SYRE catalysts: Spyre Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/syre/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
